Elektronische Entscheidungsunterstützung für mehrere Krankenhäuser bei arzneimittelbedingten akuten Nierenverletzungen (MEnD-AKI)
Elektronische Entscheidungsunterstützung für mehrere Krankenhäuser bei arzneimittelbedingter akuter Nierenverletzung (MEnD-AKI)
This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.
The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Pennsylvania
-
Altoona, Pennsylvania, Vereinigte Staaten, 16601
- UPMC Altoona
-
Farrell, Pennsylvania, Vereinigte Staaten, 16121
- UPMC Horizon
-
McKeesport, Pennsylvania, Vereinigte Staaten, 15132
- UPMC McKeesport
-
New Castle, Pennsylvania, Vereinigte Staaten, 16105
- UPMC Jameson
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Shadyside
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- UPMC Magee
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- UPMC Presbyterian/Montefiore
-
Williamsport, Pennsylvania, Vereinigte Staaten, 17701
- UPMC Williamsport
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Physician-subject Inclusion
- Physicians employed at UPMC hospital systems
- Attending physicians of record who care for patients across multiple units outside ICU/ED
- Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI
Physician-subject Exclusion
- Physicians of record who only care for ICU or ED patients
- Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients
- Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.)
Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.
Patient-subject Inclusion
- System alert identifying risk for AKI
- Patient has attending physician who is participating in the randomized clusters
- After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91
Patient-subject Exclusion
• Patients with end stage renal disease on admission, baseline eGFR <15, comfort measures only, or died before the intervention could be delivered
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Protocolized stage-based intervention
The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. |
Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician. The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted. |
|
Aktiver Komparator: Usual Care
A Cerner EMR-based AKI passive alert which is standard of care at UPMC. |
Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
Zeitfenster: up to 30 days
|
Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so ~ 3000 patients were included for the per protocol analysis to be impactful. |
up to 30 days
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
Zeitfenster: up to 30 days
|
Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert. |
up to 30 days
|
|
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
Zeitfenster: up to 30 days
|
AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians. |
up to 30 days
|
|
Nephrotoxic Burden
Zeitfenster: up to 30 days
|
Drug.days* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. *Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day. |
up to 30 days
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Azra Bihorac, MD, MS, University of Florida
- Hauptermittler: Sandra L Kane-Gill, PharmD, MS, University of Pittsburgh
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Chemisch induzierte Störungen
- Niereninsuffizienz
- Akute Nierenschädigung
- Arzneimittelbedingte Nebenwirkungen und Nebenwirkungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- STUDY20120008
- R01DK121730 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .